A major review challenges a long-standing strategy in Alzheimer’s research, suggesting that removing a hallmark brain protein may not lead to meaningful improvements for patients. A major new Cochrane review is challenging one of the most influential ideas in Alzheimer’s treatment: that clearing amyloid beta from the brain will meaningfully slow the disease. The review […]This is a curated summary.